Posted by Michael Wonder on 20 Jun 2023
FDA approves talazoparib with enzalutamide for HRR gene mutated metastatic castration-resistant prostate cancer
20 June 2023 - Today, the FDA approved talazoparib (Talzenna, Pfizer) with enzalutamide for homologous recombination repair (HRR) gene mutated metastatic castration-resistant prostate cancer (mCRPC).
Efficacy was evaluated in TALAPRO-2, a randomised, double-blind, placebo-controlled, multi-cohort trial enrolling 399 patients with HRR gene mutated mCRPC.
